# Capivasertib China PK Study

> **NCT04742036** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 16 (actual)

## Conditions studied

- Advanced Solid Tumours

## Interventions

- **DRUG:** Capivasertib
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04742036
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-22
- **Primary completion:** 2022-07-29
- **Final completion:** 2022-07-29
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04742036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04742036, "Capivasertib China PK Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04742036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*